KCTD10 p.C124W variant contributes to schizophrenia by attenuating LLPS- mediated synapse formation

• 成果类型: Article
• 署名作者: Mu, Chenjun; Liu, Pan; Liu, Liang; Wang, Yaqing; Liu, Kefu; Li, Xiangyu; Li, Guozhong; Cheng, Jianbo; Bu, Mengyao; Chen, Han; Tang, Manpei; Yao, Yuanhang; Guan, Jun; Ma, Tiantian; Zhou, Zhengrong; Wu, Qingfeng; Li, Jiada; Guo, Hui; Xia, Kun; Hu, Zhengmao; Peng, Xiaoqing; Lang, Bing; Li, Faxiang; Chen, Xiao - wei; Xu, Zhiheng; Yuan, Ling
• 署名单位: Central South University; Capital Medical University; Chinese Academy of Sciences; Institute of Genetics & Developmental Biology, CAS; Peking University; Shantou University; Central South University; Central South University
• 刊物名称: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
• ISSN/ISSBN: 0027-10409
• DOI: 10.1073/pnas.2400464121
• 发表日期: 2024-11-26
• 关键词: liquid phase-separation; TRANSITION; mechanisms; disorders; domains; binding; models

摘要

KCTD10, a member of the potassium channel tetramerization domain (KCTD) family, is implicated in neuropsychiatric disorders and functions as a substrate recognition component within the RING- type ubiquitin ligase complex. A rare de novo variant of KCTD10, p.C124W, was identified in schizophrenia cases, yet its underlying pathogenesis remains unexplored. Here, we demonstrate that heterozygous KCTD10 C124W mice display pronounced synaptic abnormalities and exhibit schizophrenia- like behaviors. Mechanistically, we reveal that KCTD10 undergoes liquid-liquid phase separation (LLPS), a process orchestrated by its intrinsically disordered region (IDR). p.C124W mutation disrupts this LLPS capability, leading to diminished degradation of RHOB and subsequent excessive accumulation in the postsynaptic density fractions. Notably, neither IDR deletion nor p.C124W mutation in KCTD10 mitigates the synaptic abnormalities caused by Kctd10 deficiency. Thus, our findings implicate that LLPS may be associated with the pathogenesis of KCTD10- associated brain disorders and highlight the potential of targeting RHOB as a therapeutic strategy for diseases linked to mutations in KCTD10 or RHOB.